Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00231426 · ClinicalTrials.gov registry record · Phase 4
ASSURE Study - Arrhythmia Single Shock DFT Versus ULV: Risk Reduction Evaluation With ICD Implantations
A Phase 4 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00231426: Completed Phase 4 study, sponsored by Boston Scientific Corporation.
NCT00231426 is a Phase 4 study that has completed, run by Boston Scientific Corporation. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00231426, a Phase 4 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
The ASSURE Study will evaluate shock conversion performance when programming the first shock of an implantable cardioverter-defibrillation (ICD) is based on an implant test consisting of either 1) a single induction of ventricular fibrillation (VF) and subsequent demonstration conversion success at 14 J or 2) an upper limit of vulnerability (ULV) test at 14 J.
Interventions
- DEVICE ICD
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-06 |
| Est. Completion | 2005-11 |
| Phase | Phase 4 |
What the finished NCT00231426 record still lists
NCT00231426 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which ICD is the first listed.
NCT00231426 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00231426 about?
NCT00231426 is a clinical study titled "ASSURE Study - Arrhythmia Single Shock DFT Versus ULV: Risk Reduction Evaluation With ICD Implantations". The ASSURE Study will evaluate shock conversion performance when programming the first shock of an implantable cardioverter-defibrillation (ICD) is based on an implant test consisting of either 1) a single induction of ventricular fibrillation (VF) and subsequent demonstration conversion success at ...
What is the current status of trial NCT00231426?
This trial is currently completed. It is a Phase 4 study. The study started on 2003-06. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00231426?
The interventions under investigation include: ICD (DEVICE).
Who is sponsoring clinical trial NCT00231426?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia